

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Catherine ROUGEOT, et al.

SERIAL NO: 10/620.462

GAU:

FILED:

July 17, 2003

EXAMINER:

FOR:

THERAPEUTIC USE OF THE SMR1 PROTEIN AND ACTIVE DERIVATIVES THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed
references are attached, where required, as are either statements of relevancy or any readily available English
translations of pertinent portions of any non-English language references.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.

☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

Each item of information contained in this information disclosure statement was first cited in a communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of
this statement.

☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Customer Number

Roland E. Martin Registration No. 48,082

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO. SERIAL NO.				
OFE			240156US0DIV 10/620,462			462	
LIST OF DEEEDENCES OUTED BY ADDITIONE			APPLICANT				
C.P. Ob	LIST OF REFERENCES CITED BY APPLICANT			Catherine ROUGEOT, et al.			
温		37		FILING DATE		GROUP	
(A)				July 17, 2003	_		
EXAMPLE S							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
KAC	AA	6,589,750	07-08-03	ROUGEOT et al.			
	AB						
	AC						
6	AD						
	AE						
1	AF						
	AG						
	AH		1				
	Al				 	f	
	AJ						
	AK		 				
	AL		 -		-		
	AM						
	AN						
		· · · · · · · · · · · · · · · · · · ·	FO	REIGN PATENT DOCUMENTS	.I		
		DOCUMENT NUMBER	DATE	COUNTRY		YES	TRANSLATION S NO
	AD			,		TEC	S NO
	AP						
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
		OTHER R	FERENCES (Including Author, Title, Date, Pertiner	t Pages e	te)	<u>_</u>
	AW						
	AX						
	AY	0					
	AZ				Addi	tional Refe	rences sheet(s) attached
Examiner		/Karen A. Can	ella, Ph	.D./	Date Cor	nsidered	06/26/2006
*Examiner: In conformance	itial if n	eference is considered, ot considered. Include co	whether or not	t citation is in conformance with MPEP 6 with next communication to applicant.	09; Draw lii	ne through	citation if not in



LIST OF RELATED CASES

Docket Number	Serial or Patent Number	Filing or <u>Issue Date</u>	Inventor/ <u>Applicant</u>
240988US-0-CIP	10/024,535	12/21/01	MARCEL, et al.
00660-0158-0 PCT	09/367,703	10/13/99	ROUGEOT, et al.
238578US-0-X PCT	10/451,064	6/20/03	ROUGEOT, et al.
239675US-0	6,589,750	7/8/03	ROUGEOT, et al.
239676US-0-DIV	10/435,564	5/12/03	ROUGEOT, et al.
239682US-0-CONT	10/315,445	12/10/02	MARCEL, et al.
240156US-0-DIV*	10/620,462	7/17/03	ROUGEOT, et al.

^{*}Present Application; listed for information NFO/wal

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Catherine ROUGEOT, et al.

SERIAL NO: New Application

GAU:

FILED:

Herewith

EXAMINER:

FOR:

THERAPEUTIC USE OF THE SMR! PROTEIN AND ACTIVE DERIVATIVES THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449 and cited in the attached International Search Report. Copies of the listed references were previously filed in PCT/EP98/00956 filed on February 19, 1998.
- A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADZ, P.C.

Norman F. Oblon

Registration No. 24,618

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Thomas M. Cunningham Registration No. 45,394

Farm PTO 1449	U.S. DEPARTMENT OF COMMERCE			ATTY DOCKET NO.		SERIAL NO.		
(Modified)		PATENT AND TRADEMARK OFFICE		240156US0DIV		New Application		
				APPLICANT				
LIST OF REFERENCES CITED BY APPLICANT				Catherine ROUGEOT, et al.				
				FILING DATE		GROUP		
				Herewith				
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB FILING DATE CLASS IF APPROPRIATE		
KAC	AA	5 219 548	6/15/93	YANG, David J. et al.				
	AB							
	AC							
	AD							
	AE							
	AF							
	AG			·				
	AH							
	Al							
	AJ					_		
	AK							
	AL							
	AM							
	AN							
]			FO	REIGN PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY TRANSLAT			LATION NO	
KAC	· AO	WO 90 03981	4/19/90	WIPO				
KAC	AP	WO 95 00848	1/5/1995	WIPO				
KAC AQ EP 0 240 975 10/14/87 EP		EP						
1000	AR							
	AS							
	AT							
	AU							
	AV							
		OTHER RE	FERENCES (Including Author, Title, Date, Pertinent	Pages, e	tc.)		
		ROUGEOT et al., "Sel	ective process	ing of submandibular rat 1 protein at diba	sic deava	ge sites." (UR. J.	BIOCHEM., vol.
KAC	ROUGEOT et al., "Selective processing of submandibular rat 1 protein at dibasic cleavage sites," EUR. J. BIOCHEM., vol. AW 219, 1994, pp. 765-773.							
KAC	AX	PURDIE et al., "Effects of danazol on mineral homeostasis in normal postmenopausal women: preliminary communication," JOURNAL OF ROYAL SOCIETY OF MEDICINE, vol. 80, no. 11, 1987, pp. 681-682.						
KAC	AY	ROUGEOT et al., "TARGETS FOR SMR1-PENTAPEPTIDE SUGGEST A LINK BETWEEN THE CIRCULATING PEPTIDE AND MINERAL TRANSPORT," AM. J. PHYSIOLOGY, vol. 273, no. 4 PT 2, October 1997, pp. R1309-1320.						
KAC	AZ	SINGER et al., "Recent evolution of genes encoding the prohormone-like protein SMR1 in the rat submandibular gland," DNA CELL BIOLOGY, vol. 14, Additional References sheet(s) attached						
Examiner		no. 2, 1995, pp. 137-1 /Karen A. Car		n.D./	Date Cor	sidered		06/26/2006
				t citation is in conformance with MPEP 60 with next communication to applicant.	9; Draw li	ne through		

Form PTO 1449		U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO.	SE	ERIAL NO.				
(Modified)		PATENT AND TRADEMARK OFFICE	240156US0DIV		New Application				
			APPLICANT						
LIST OF	REFE	RENCES CITED BY APPLICANT	Catherine ROUGEOT, et al.						
			FILING DATE	GF	ROUP				
			Herewith						
		OTHER REFERENCES (Including Author, Title, Date, Pertinent	Pages, etc.)					
KAC	AAA	COURTY et al., "Episodic evolution and rapid divergence of members of the rat multigene family encoding the salivary prohormone-like protein SMR1," MOLECULAR BIOLOGY AND EVOLUTION, vol. 12, no. 6, 1996, pp. 758-766.							
KAC	AAB	DREWS R et al., "PROTEOLYTIC MATURATION OF PROTEIN C UPON ENGINEERING THE MOUSE MAMMARY GLAND TO EXPRESS FURIN," PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 92, no. 23, November 1995, pp. 10462-10466.							
KAC	AAC	DRUCKER et al., "Regulation of the Biotechnology, (Abstract), 1997.	biological activity of glucagon-like peptide	2 in vivo by o	lipeptidyl peptidase," Nature				
	AAD								
	AAE								
	AAF								
	AAG								
	AAH								
	AAI								
	AAJ								
	AAK								
	AAL								
	AAM								
	AAN								
	AAO								
	AAP								
	AAQ								
Examiner		/Karen A. Canella, Ph		Date Consid	06/26/2006				
			t citation is in conformance with MPEP 60 with next communication to applicant.	9; Draw line t	through citation if not in				